View ValuationIntegrum 将来の成長Future 基準チェック /06現在、 Integrumの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Medical Equipment 収益成長12.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • Nov 13Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023Integrum AB (publ) provided earnings guidance for the second quarter of 2023. The revenue for second quarter is expected to be at SEK 27.5 million (SEK 20.2 million), which corresponds to an increase of 36.2% in comparison to last year. The operating profit for second quarter is expected to be at SEK 6.4 million (SEK 0.9 million). Excluding direct currency effects, the operating profit is expected to be at SEK 4.1 million (loss of SEK 5.2 million). The increase in operating profit can be attributed to both the increase in activity but also an improved cost structure for operating costs.Breakeven Date Change • Sep 08Forecast to breakeven in 2023The analyst covering Integrum expects the company to break even for the first time. New forecast suggests the company will make a profit of kr12.0m in 2023. Average annual earnings growth of 101% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesReported Earnings • Jun 04Full year 2026 earnings released: kr1.98 loss per share (vs kr1.52 loss in FY 2025)Full year 2026 results: kr1.98 loss per share (further deteriorated from kr1.52 loss in FY 2025). Revenue: kr96.1m (down 1.4% from FY 2025). Net loss: kr46.3m (loss widened 50% from FY 2025). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings.お知らせ • Jun 04+ 3 more updatesIntegrum AB (publ) to Report Second Half, 2027 Results on Jun 10, 2027Integrum AB (publ) announced that they will report second half, 2027 results on Jun 10, 2027Board Change • May 20High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. Founder, Owner, Chief Medical & Scientific Officer and Chairman of the Board Rickard Branemark is the most experienced director on the board, commencing their role in 2009. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Feb 12Integrum AB (publ) Announces Executive ChangesIntegrum AB (publ) announced that Jeff Zanni, President US, is leaving the company. Dr. Rickard Brånemark takes on the role as Chief Medical and Scientific Officer on a consulting basis, with responsibility for leading the training of surgeons in the use of the company's implant system both in the US and other parts of the world. On March 16, Per Nilsson, with extensive experience in production and supply chain management within the MedTech sector, will join as Chief Supply Chain Officer. Following the organizational changes, Integrum's management team consists of Martin Hillsten, Chief Executive Officer, Louise Wåhlin, Chief Financial Officer, Dr. Annika Fahlén, Director of Quality Assurance and Regulatory affairs, Dr. Rickard Brånemark, Chief Medical and Scientific Officer, and Per Nilsson, Chief Supply Chain Officer (assuming the role on March 16).お知らせ • Oct 31Integrum AB (publ), Annual General Meeting, Oct 29, 2025Integrum AB (publ), Annual General Meeting, Oct 29, 2025.お知らせ • Oct 16Integrum AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 42.668656 million.Integrum AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 42.668656 million. Security Name: Class B Shares Security Type: Common Stock Securities Offered: 5,333,582 Price\Range: SEK 8 Transaction Features: Rights Offeringお知らせ • Sep 01Integrum AB (publ) to Report Q4, 2026 Results on Jun 04, 2026Integrum AB (publ) announced that they will report Q4, 2026 results on Jun 04, 2026お知らせ • Jun 03+ 1 more updateIntegrum AB (publ) to Report Q3, 2026 Results on Mar 02, 2026Integrum AB (publ) announced that they will report Q3, 2026 results on Mar 02, 2026お知らせ • May 06Integrum AB (Publ) Announces CEO ChangesIntegrum AB (publ) announced the appointment of Martin Hillsten as the new CEO, effective immediately. He succeeds acting CEO Scott Flora, who will continue to support US marketing activities in an advisory capacity and remain on the company's Board of Directors. Martin Hillsten most recently served as CEO of Integration Diagnostics and has extensive experience in the sales and marketing of advanced medical devices in the US and other parts of the world. Integrum is implementing a strategic shift to accelerate market penetration of the OPRA® Implant System, concentrating on the US and prioritized European countries. The strategy includes a focus on selected Centers of Excellence, a strengthened aftermarket approach, and an optimization of operations that is expected to generate cost savings of up to SEK 20 million annually when fully implemented in early 2026. Martin Hillsten, born in 1978, holds a Bachelor of Business Administration from the University of Lincoln, UK, and has 20 years of experience in the life sciences industry with an emphasis on implant products and diagnostic imaging. He most recently served as CEO of Integration Diagnostics, a company that develops, manufactures and markets products to measure the stability of an implant and its ability to integrate with bone tissue (osseointegration). In addition, Martin Hillsten has held senior sales and marketing positions at Bracco Diagnostics. He currently owns 42,000 shares in Integrum. Scott Flora will continue to support the implementation of Integrum's marketing strategy in the US in an advisory role and will remain on the company's Board of Directors.お知らせ • Mar 18Integrum AB (publ) Announces Newly Published Independent Study from the Walter Reed National Military Medical Center in Bethesda, Maryland, U.SIntegrum AB (publ) announced that a newly published independent study from the Walter Reed National Military Medical Center in Bethesda, Maryland, U.S., provides compelling evidence of OPRATM Implant System's treatment effectiveness in transfemoral amputees. The study demonstrates significant functional improvements over traditional socket prostheses, an important validation of Integrum's innovative technology and its clinical benefit in patients who have undergone amputation. The two-year follow-up study (Level II Evidence) includes the latest and most advanced version of the OPRATM Implant system, which was introduced in 2017. The study results highlight several key benefits for patients using the implant system, including increased prosthetic use, improved mobility, and enhanced quality of life. Importantly, the study reveals improved outcomes compared to previously published data, including fewer infections and complications, and a 100% implant survival rate. Collectively, the insights gathered from this study will be useful in driving further adoption of the technology by US health providers, as well as to increase the awareness of the OPRATMImplant System among health professionals and potential patients. The study was authored by Benjamin K. Potter, MD, Jonathan A. Forsberg, MD, PhD, LCDR Ashley B. Anderson, MD, MD, MD, MD., Jason M. Souza, MD, and Julio Rivera, PhD, and recently published in Clinical Orthopaedics and Related Research (CORR).お知らせ • Mar 03Integrum AB (publ) to Report Q1, 2026 Results on Sep 01, 2025Integrum AB (publ) announced that they will report Q1, 2026 results on Sep 01, 2025お知らせ • Feb 19Integrum AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 31 million.Integrum AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 31 million. Security Name: Class B Shares Security Type: Common Stock Securities Offered: 1,937,500 Price\Range: SEK 16 Transaction Features: Subsequent Direct Listingお知らせ • Jan 22Integrum AB (Publ) Announces Board AppointmentsIntegrum AB (publ) announced the new board members Kristofer Westergren and Anette Lindqvist elected on the Extra General Meeting. Kristofer Westergren represents a group of major private shareholders in Integrum AB. He has followed the company closely for several years and thus has extensive knowledge of the business. Kristofer Westergren has extensive experience from the stock market as an investor and financial advisor to company managements in listed companies. He has founded and invested in several growth companies, and he has worked on the board of directors with operational improvements, value-creating acquisitions and company sales such as Sharkmob AB, KitchenTime Group AB and Corpura Fondkommission AB. Anette Lindqvist holds a degree in Business Administration from the Gothenburg School of Economics and Executive Independent Courses from Harvard Business School in Boston and the Indian Institute of Management in Bangalore. With over 30 years of experience in the life science sector, she has held several senior positions in business development and senior positions in finance at companies such as AstraZeneca Plc., SOBI, Getinge and Mölnlycke Healthcare. She has also been active in GU Ventures and Chalmers. Anette is the founder of Lynton Management AB. Currently, she is the Deputy CEO and Chairman of the Board of both Lynton Management AB and Bueneman Medic AB. She is also the CFO at Xbrane Biopharma.After the Extra General Meeting the Board of Directors in Integrum consists of the Chairman of the Board Bengt Sjöholm and the board members Rickard Brånemark, Karin Wingstrand, Cecilia Wikström, Andrew Christensen, Scott Flora, Anette Lindqvist and Kristofer Westergren.お知らせ • Dec 20Integrum AB (Publ) Announces Board ChangesIntegrum AB (publ) announced that the election committee of Integrum plans to propose the election of Anette Lindqvist as board member at an extra general meeting. Board member Patric Lindgren has informed the election committee that he has resigned from the board on December 18. Notice of the extraordinary general meeting will be issued shortly. Anette Lindqvist has a degree in business administration from Gothenburg School of Economics and executive independent courses from Harvard Business School in Boston and the Indian Institute of Management in Bangalore. With over 30 years of experience in the Life Science sector, she has held several leading positions in business development and senior positions in finance at companies such as AstraZeneca Plc., SOBI, Getinge and Mölnlycke Healthcare. She has also worked within GU Ventures and Chalmers. Anette is the founder and chairman of the board of Lynton Management AB. Currently, she is deputy managing director and chairman of the board for both Lynton Management AB and Bueneman Medic AB.お知らせ • Sep 18Inger Rydin Announces Executive ChangesIntegrum AB (publ) announces that Inger Rydin has been appointed interim COO and will be responsible for operations at the office in Mölndal, Sweden. Inger, who served as interim COO at Integrum from 2021 to 2023, will be part of the management team. She takes office immediately. Inger Rydin served as acting COO at Integrum from 2021 to 2023. She built a career in various leading strategic and operational positions at Essity, Mölnlycke Healthcare and Coloplast. Inger has also been CEO of fast-growing owner-managed companies and has served on the boards of companies listed in Oslo and Stockholm.お知らせ • Sep 16+ 1 more updateIntegrum Announces Change in Chief Executive OfficerIntegrums CEO Rickard Brånemark has on September 15, 2024 agreed together with the board that he will leave the CEO role. The board announces that Scott Flora, board member since 2023, has been appointed acting CEO of Integrum AB. He takes office with immediate effect. The board will immediately start the recruiting process of a new CEO. Scott Flora was born in 1955 and is an American citizen and has a bachelor's degree in marketing from Millikin University in the United States and has attended INSEADs global programs in France. Scott is a MedTech veteran who has held leadership positions at Smith & Nephew Ioptex (Ophthalmology), and Covidien Surgical Device, Medtronic. Scott has previously, among other things, been CEO of Invuity now part of Stryker, OmniGuide, and Conventus Orthopaedics. He is now in addition to acting CEO and board member of Integrum, chairman of the board of Palliare Ltd, board member of MAKO Surgical, now part of Stryker, board member of TubeWriter and Origami Surgical. Scott has previously advised Metalmark Capital and CVC Capital. Scott owns no shares in the company.Reported Earnings • Sep 03First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: kr19.8m (down 4.6% from 1Q 2024). Net loss: kr9.41m (loss widened 229% from 1Q 2024). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.お知らせ • Aug 29Integrum AB (publ), Annual General Meeting, Sep 25, 2024Integrum AB (publ), Annual General Meeting, Sep 25, 2024, at 16:00 W. Europe Standard Time. Location: goco health innovation city, gemenskapens g 9, 431 53, molndal SwedenBoard Change • Jun 19Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director Patric Lindgren was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.New Risk • Jun 15New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (25% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (6.5% increase in shares outstanding). Market cap is less than US$100m (€90.0m market cap, or US$96.3m).Reported Earnings • Jun 05Full year 2024 earnings released: EPS: kr0.23 (vs kr0.88 loss in FY 2023)Full year 2024 results: EPS: kr0.23 (up from kr0.88 loss in FY 2023). Revenue: kr116.3m (up 50% from FY 2023). Net income: kr4.17m (up kr20.4m from FY 2023). Profit margin: 3.6% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.お知らせ • May 31+ 3 more updatesIntegrum AB (publ) to Report Q3, 2025 Results on Mar 03, 2025Integrum AB (publ) announced that they will report Q3, 2025 results on Mar 03, 2025お知らせ • May 16Integrum Announces It Has Been Granted A Registered Trademark for OPRA® Implant System in the EuIntegrum (publ) announced that the European Union Intellectual Property Office, EUIPO, has approved Integrum's product registration application for the OPRA® Implant System. Until now, the OPRA® Implant system has been an unregistered mark without legal protection. As it is granted a registered trademark, Integrum now obtains unitary immaterial protection for the product in the entire territory of the EU.Reported Earnings • Mar 05Third quarter 2024 earnings released: EPS: kr0.05 (vs kr0.74 loss in 3Q 2023)Third quarter 2024 results: EPS: kr0.05 (up from kr0.74 loss in 3Q 2023). Revenue: kr32.9m (up 68% from 3Q 2023). Net income: kr846.0k (up kr14.4m from 3Q 2023). Profit margin: 2.6% (up from net loss in 3Q 2023). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.お知らせ • Feb 24Integrum AB (publ) to Report Q3, 2024 Results on Feb 29, 2024Integrum AB (publ) announced that they will report Q3, 2024 results on Feb 29, 2024Reported Earnings • Dec 07Second quarter 2024 earnings released: EPS: kr0.21 (vs kr0.21 in 2Q 2023)Second quarter 2024 results: EPS: kr0.21 (down from kr0.21 in 2Q 2023). Revenue: kr36.3m (up 69% from 2Q 2023). Net income: kr3.88m (down 3.8% from 2Q 2023). Profit margin: 11% (down from 19% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.New Risk • Dec 06New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 8.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings are forecast to decline by an average of 8.7% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable next year (kr17m net loss next year). Market cap is less than US$100m (€64.2m market cap, or US$69.3m).お知らせ • Nov 15Integrum AB (publ) Plans to Submit a PMA Application to the FDA for the Use of OPRA in Transhumeral Implantations Based on Existing Clinical DataIntegrum (publ) announced that the company has held a pre-submission meeting with the US Food and Drug Administration (FDA) to discuss the regulatory pathway for the use of Integrum's OPRA Implant System in transhumeral amputations. Based on the conclusions from the meeting, Integrum plans to submit a Pre-Market Approval (PMA) application based on existing clinical data. Since December 2020, the OPRATM Implant System holds a PMA for the treatment of transfemoral (above-knee) amputations. As the OPRATM Implant System is equally functional in transhumeral (above-elbow) amputations, Integrum aims to broaden the regulatory approval in the US. After a recent pre-submission meeting held with the FDA and additional internal analysis and dialogue with the FDA, Integrum has reason to believe that existing clinical data on the transhumeral (above elbow) amputation level may be sufficient to qualify for a PMA. Integrum will therefore intensify the work to compile and submit a PMA application within the first half of 2024.お知らせ • Nov 13Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023Integrum AB (publ) provided earnings guidance for the second quarter of 2023. The revenue for second quarter is expected to be at SEK 27.5 million (SEK 20.2 million), which corresponds to an increase of 36.2% in comparison to last year. The operating profit for second quarter is expected to be at SEK 6.4 million (SEK 0.9 million). Excluding direct currency effects, the operating profit is expected to be at SEK 4.1 million (loss of SEK 5.2 million). The increase in operating profit can be attributed to both the increase in activity but also an improved cost structure for operating costs.お知らせ • Nov 11Integrum AB (publ) to Report Q2, 2024 Results on Dec 04, 2023Integrum AB (publ) announced that they will report Q2, 2024 results on Dec 04, 2023お知らせ • Nov 10Integrum (Publ) Announces US Department of Defense Decided to Fully Fund a Clinical Study of OPRA(TM) Implant System on Up to 30 Patients with Transtibial (Below-Knee) AmputationsIntegrum (publ) announced that the US Department of Defense has decided to fully fund a clinical study of OPRA(TM) Implant System on up to 30 patients with transtibial (below-knee) amputations. As previously announced, the study will be performed by the Walter Reed National Military Medical Center in Bethesda, Maryland. Integrum will supply OPRA(TM) Implant Systems to Walter Reed on commercial terms. The OPRA(TM) Implant System clinical study on the below-knee amputation level recently received FDA approval, and recruitment to the study will start as soon as the protocol is approved by the Investigational Research Board (IRB). Once the study is finalized, Integrum will be able to use the data in any future regulatory process.お知らせ • Oct 31Integrum's Opra™? Implant System Gets Fda Approval for Clinical Study on Below-Knee AmutationationsIntegrum (publ) announced that the company's OPRA Implant system is approved by FDA to be used in a clinical study on below-knee amputations in the US. The clinical study will be important for the future approval of the OPRA™? Implant System on the below-knee amputations level, which is the most frequent amputation level. The study will be performed by the Walter Reed National Military Medical Center.New Risk • Oct 18New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: kr6.0m Forecast net loss in 1 year: kr7.2m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (kr7.2m net loss next year). Market cap is less than US$100m (€51.6m market cap, or US$54.3m).お知らせ • Oct 13Integrum (Publ) Announces Long-Term Follow-Up Patient Who Received A Human-Machine Bionic Hand Prosthesis, UtilizingIntegrum (publ) announced that the long-term follow-up of a patient who received a human-machine bionic hand prosthesis, utilizing the company's innovative implantable solution, has shown successful results. The groundbreaking system represents a future standard of advanced prosthetic solutions. The patient case involves a Swedish woman who lost her right hand in a tragic accident over 20 years ago. Following reconstructive surgery, the woman received a below-elbow prosthesis based on Integrum's OPRATM Implant System solution. The system was further refined advanced e-OPRATM system with implanted electrodes, connected to a sophisticated AI system with the capability of relaying impulses, both to and from, a bionic hand equipped with heat and touch sensors.お知らせ • Oct 12Integrum Announces Long-Term Integrated Bionic Hand Enriched with Motor and Sensory AIIntegrum (publ) announced that the long-term follow-up of a patient who received a human-machine bionic hand prosthesis, utilizing the company's innovative implantable solution, has shown successful results. The system represents a future standard of advanced prosthetic solutions. The patient case involves a Swedish woman who lost her right hand in a tragic accident over 20 years ago. Following reconstructive surgery, the woman received a below-elbow prosthesis based on Integrum's OPRATM Implant System solution. The system was further refined advanced e-OPRATM system with implanted electrodes, connected to a sophisticated AI system with the capability of relaying impulses, both to and from, a bionic hand equipped with heat and touch sensors. The complete system has been used at home, allowing the carrier to perform simple and motorically complex everyday tasks. This is the first time clinicians and researchers have been able to achieve a long-term human-machine interface, connecting residual bones, nerves, and muscles into an electronic system to regain mobility.お知らせ • Oct 11Integrum Receives Unitary Patent for Neuromotus in the EUIntegrum (publ) announced that the company has received a Unitary Patent approval pertaining to NeuromotusTM - a clinical innovation aimed at treating patients suffering from Phantom Limb Pain. The new patent process, which was installed by the EU in June 2023, grants immediate proprietary rights to Integrum in 17 separate European countries. Integrum develops NeuromotusTM, an innovative therapy designed to treat patients suffering from phantom pain. The therapy is based on a non-invasive technology utilizing smart devices to process and decode electrical muscle signals. These are connected to virtual and augmented reality (AR-VR) systems, allowing the patient to control the missing limb in a virtual environment. This form of treatment has been proven effective to combat chronic pain. The current patent will be taken to effect on 23rd of August, 2023, and thus grants Integrum exclusive commercial rights for NeuromotusTM on several European key markets, including Germany, Benelux, France, Italy, and Sweden. The patent will be valid until 19th of December, 2034.お知らせ • Oct 10Integrum AB (Publ) Appoints Scott Flora as Full Board MemberIntegrum AB (publ) announced that Scott Flora was recently elected as full member of the company's board at the annual general meeting. Mr. Flora was appointed as Adjunct Board Member in May 2023. At the annual general meeting on September 27, he was elected full member of the board together with Rickard Brånemark, Andrew Christensen, Bengt Sjöholm, Karin Wingstrand, Patric Lindgren, and Cecilia Wikström, who were all re-elected. Scott Flora serves concurrently as chairman of the Board at Palliare Ltd. and New View Surgical, and as board member at CytoVeris and Origami Surgical. He has previous experience as board member from Invuity (acquired by Stryker), MAKO Surgical, and Tengion. Mr. Flora is active as Strategic Advisor to CareSyntax, MiCarePath, and Integrum. Furthermore, he has over 40 years of experience from C-suite leadership positions in global companies, including Invuity, Conventus Orthopaedics, OmniGuide Surgical, and Smith & Nephew Orthopedics.お知らせ • Sep 14Integrum Initiates A Strategic Review Process to Accelerate GrowthIntegrum AB (publ) announces that its Board of Directors has initiated a review and evaluation of strategic alternatives to further accelerate the global roll-out of its unique OPRA™Implant System. Integrum has developed and markets the OPRA™ Implant System, an advanced prosthesis fixation system for individuals with mobility challenges due to limb amputation. Integrum's implant solution is surgically inserted into the patient's skeleton - providing greatly increased functionality and significantly fewer complications than conventional socket prostheses. As a next step in revolutionizing the prosthesis market, Integrum is developing the e-OPRATM Implant System - the world's first mind-controlled robot prosthesis capable of transmitting sensory feedback. Integrum is experiencing rapid growth of its business and recently reported its highest quarterly sales revenue ever. The long-term goal is to establish OPRATM Implant Systems as the worldwide standard of care for individuals with mobility challenges. The strategic review aims to ensure that the global roll-out of Integrum's implant systems is conducted most efficiently, in the interest of both patients and shareholders. As part of the process, the Board will consider a full range of strategic alternatives, including mergers or other business combinations, strategic investments, sale of all or a portion of the company's assets, corporate sale, or other significant transactions. As part of the strategic review process, Integrum has engaged Incentrum - a global merchant bank based in New York City - as its financial advisor to advise the company regarding this broad and comprehensive review and analysis of strategic alternatives. Integrum has not set a timetable for completion of the process and does not plan to provide any updates on developments unless and until the company executes a definitive agreement with respect thereto or the Board determines to conclude the strategic review. While the company intends to evaluate all options fairly to maximize shareholder value, there can be no assurance that the strategic review process will result in any transaction, or if a transaction is undertaken, as to its terms or timing.お知らせ • Sep 09Integrum AB Receives Reimbursement Code for Axor IIIntegrum (publ) announced that The Centers for Medicare and Medicaid Services (CMS) have granted theosseointegrated external prosthetic connection device Axor II a new reimbursement code. The new code, which is expected to take effect in October, is connected to a set reimbursement that will help to drive growth in the US. The new CMS-specific code is granted based on a preliminary benefit category determination that the Axor(TM) II Ossteointegrated External Prosthetic Connection Device is used in addition to a lower extremity prosthesis and, therefore, falls under the Medicare benefit for artificial legs (prosthetics). Since the Axor(TM)II utilizes a standard 4-hole male/female mounting system, the OPRA(TM) Implant System can be connected to commercially available prosthetic systems that utilize this standardized connection method. The Axor(TM) II acts like aski-binding and releases the prosthesis if overload occurs, reducing the risk of damage to the implant and the skeleton. Axor(TM) II was first approved under a Premarket Approval (PMA) application by the Food and Drug Administration (FDA) on December 18, 2020.お知らせ • Jul 14Integrum (Publ) Announces First Case Study of A Person with Above-Elbow Implantation Obtains Unprecedented Control of Every Finger in A Bionic HandIntegrum (publ) announced that the first case study of a person with above-elbow amputation obtaining unprecedented control of every finger in a bionic hand has been published in Science Translational Medicine. By combining Integrum's OPRA™? Implant System and e-OPRA™? Implant System with revolutionary surgical and engineering advancements and AI algorithms, the user's intentions were translated into the movement of the bionic fingers. The scientific paper illustrates how Integrum's technology combined with advanced reconstructive surgery and AI for the first time, made it possible for an above-elbow amputee patient to control every finger of a prosthetic hand as if it were his own. The surgery took place at the Sahlgrenska University Hospital and combined new microsurgical techniques with sophisticated implanted electrodes that provide single-finger control of a prosthetic arm as well as sensory feedback. The embedded neuromuscular sensors were connected to an electronic system via Integrum's bone-anchored interface (OPRA(TM) Im plant System and e-OPRA(TM) Implant System), and AI algorithms in the electronic system translated the user's intentions into prosthetic finger movements.お知らせ • Jun 17Integrum AB (Publ) Announces Management ChangesIntegrum (publ) announced that the company has appointed Jeffrey Zanni as President, U.S., succeeding Thomas Dugan, who has decided to resign from his position. Jeffrey Zanni joins Integrum from Conventus Flower Orthopedics, where he has been Chief Commercial Officer. He has more than 20 years of success in the surgical and medical device industry and has a proven track record of successfully developing and leading highly effective sales teams. Jeffrey Zanni has previously held several executive positions at companies like Vyaire Medical, Tornier Orthopedics Stryker Orthopedics, and Pfizer. Jeffrey Zanni has experience launching new products and developing effective clinician and patient support programs from his previous positions. He has a deep understanding of how to partner with key stakeholders within the U.S. Jeffrey Zanni will join Integrum on 2023-07-03.New Risk • Jun 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (€27.0m market cap, or US$29.0m).Reported Earnings • Jun 09Full year 2023 earnings releasedFull year 2023 results: Revenue: kr98.5m (up 62% from FY 2022). Net loss: kr3.72m (down 118% from profit in FY 2022). Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany.お知らせ • May 12Integrum Announces the Appointment of Scott Flora as Adjunct Board MemberIntegrum (publ) announced that Scott Flora has been appointed as an adjunct board member effective immediately. Scott Flora brings vast and extensive competence to the company as Integrum is reinforcing the company's position as a leader of osseointegrated implant systems. Scott Flora has over 40 years of experience in strategic and leadership roles in the healthcare sector, particularly in surgical devices, and has held prominent leadership positions at companies including Covidien and Smith & Nephew. He is currently Chairman of the Board at Palliare Ltd. and a board member at CytoVeris and New View Surgical. Scott Flora also serves as Strategic Advisor to CareSyntax, MiCarePath, and Integrum. He has previously held several leading positions roles as President and CEO of Invuity (acquired by Stryker), Executive Director of Conventus Orthopaedics, President and CEO of OmniGuide Surgical, President of Covidien's Surgical Device Group, President of Smith& Nephew Orthopedic Reconstruction and General Manager at Smith&Nephew Trauma. Scott Flora has also served on the company boards of Invuity (acquired by Stryker), MAKO Surgical, and Tengion.Reported Earnings • Mar 04Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr22.1m (up 58% from 3Q 2022). Net loss: kr13.6m (down kr14.1m from profit in 3Q 2022). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.お知らせ • Jan 21Integrum (publ) Appoints Annika Fahlén as Director of Quality Assurance and Regulatory Affairs, Effective 1 April 2023Integrum (publ) announced that the company has appointed Annika Fahlén as Director of Quality Assurance and Regulatory Affairs, QARA. Annika Fahlén will join the company on 1 April 2023 and will be part of the management team. Annika Fahlén has vast experience in the field of Quality Assurance and Regulatory Affairs working at Mölnlycke, Getinge, Qing and Abigo. She will join Integrum from a position as Regulatory Affairs Quality Assurance Director at Essity.お知らせ • Jan 20Integrum AB (Publ) Announces Dennis Baecklund to Leave the Company as CFOIntegrum AB (publ) announces that the company's CFO Dennis Baecklund has decided to leave the company. He will remain in his position until the end of March 2023 and the recruitment of a successor will begin immediately. Dennis Baecklund joined Integrum as Chief Financial Officer in October 2019.Reported Earnings • Dec 02Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr32.4m (up 173% from 2Q 2022). Net income: kr2.32m (down 86% from 2Q 2022). Profit margin: 7.2% (down from 136% in 2Q 2022). Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany.お知らせ • Dec 01Integrum Provides an Update on the Clinical Development Programs of e-OPRATM Implant System and NeuromotusIntegrum (publ) provides an update on the clinical development of its mobility-transforming implant solution e-OPRATM Implant System, and NeuromotusTM - a cutting-edge technology developed to prevent severe pain in limb loss patients. e-OPRATM Implant System: The clinical development of e-OPRA™ Implant System focuses not only on providing prosthesis users with the benefits of a bone-anchored implant solution but also on the possibilities of mind-controlled artificial limb movement, as well as re-established sensory feedback to the central nervous system. e-OPRATM is currently being evaluated in three clinical trials. Two clinical trials are being conducted in the US, at the Brigham and Women's Hospital in collaboration with Massachusetts Institute of Technology in Boston, and University of California in San Francisco,. The trials aim to evaluate the extent by which a person who has received the e-OPRA™ Implant System can exhibit full neural control over a neuro-mechanical prosthetic system, as well as the normalization in walking metrics. The functionality of the e-OPRATM Implant System is being evaluated at two levels: in patients who have undergone amputation above the knee, and in patients with below knee amputations. The third trial is conducted at the Sahlgrenska University Hospital, in Sweden. This trial aims to evaluate potential improvements in prosthetic control in patients who have received e-OPRATM Implant System following upper limb amputation. To assess prosthetic control performance, the trial will measure long-term myoelectric signal stability and sensory perception over twelve months.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director Patric Lindgren was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Nov 02Investor sentiment improved over the past weekAfter last week's 25% share price gain to €2.63, the stock trades at a trailing P/E ratio of 27.5x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total loss to shareholders of 71% over the past year.お知らせ • Oct 12Integrum AB (publ) Is Granted Patent Approval for Its OPRA Implant System from the Us Patent and Trade OrganizationIntegrum (publ) announced that the company has received a patent approval in the US describing components and design features of the OPRATM Implant System, including elements that were implemented in 2017 and later were granted a PMA approval in late 2020. The patent period extends until 2044. Integrum develops the OPRATM Implant System, a revolutionary implant technology based on the company's deep expertise and innovations in osseointegration, that help amputees regain normal mobility and quality of life. The current patent includes claims covering the system as a whole, including the anchoring solution for attaching a prosthesis into the human body as well as the abutment and the abutment screw. These claims extend beyond transfemoral applications, which currently make up the majority of treatment cases, to include treatment in other types of long bone prosthetic applications, such as the upper arm or lower leg. Further, the claims cover design features for the connection between the abutment and the fixture, allowing a pathway for communication of physical and biophysical signals between inside and outside of the human body. Such design aspects are of vital importance to, for example, the e-OPRATM Implant System - Integrum's state-of-the-art mind-controlled robotic prosthesis. The patent grants Integrum exclusivity to OPRATM Implant System ranging from October 11th,2022, until 2044 and is of vital importance to the continued commercial success on the world'slargest medical technology market.Valuation Update With 7 Day Price Move • Sep 23Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €2.78, the stock trades at a trailing P/E ratio of 28.5x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total loss to shareholders of 68% over the past year.Valuation Update With 7 Day Price Move • Sep 07Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to €3.40, the stock trades at a trailing P/E ratio of 34.7x. Average forward P/E is 26x in the Medical Equipment industry in Germany. Total loss to shareholders of 65% over the past year.Reported Earnings • Sep 01First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr25.2m (up 95% from 1Q 2022). Net loss: kr550.0k (down 145% from profit in 1Q 2022). Over the next year, revenue is forecast to grow 76%, compared to a 8.0% growth forecast for the Medical Equipment industry in Germany.Valuation Update With 7 Day Price Move • Jul 26Investor sentiment improved over the past weekAfter last week's 18% share price gain to €5.03, the stock trades at a trailing P/E ratio of 44.3x. Average forward P/E is 29x in the Medical Equipment industry in Germany. Total loss to shareholders of 37% over the past year.Valuation Update With 7 Day Price Move • Jun 20Investor sentiment improved over the past weekAfter last week's 20% share price gain to €4.29, the stock trades at a trailing P/E ratio of 38.2x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total loss to shareholders of 42% over the past year.Reported Earnings • Jun 11Full year 2022 earnings releasedFull year 2022 results: Revenue: kr76.7m (up 75% from FY 2021). Net income: kr21.3m (up kr23.4m from FY 2021). Profit margin: 28% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 27%, compared to a 7.1% growth forecast for the industry in Germany.お知らせ • Jun 11+ 2 more updatesIntegrum AB (publ) to Report Q1, 2023 Results on Sep 02, 2022Integrum AB (publ) announced that they will report Q1, 2023 results on Sep 02, 2022お知らせ • May 20+ 1 more updateIntegrum AB (publ) Announces Board ChangesIntegrum AB (publ) announced Rickard Brånemark resigned as Chairman of the Board, and the Board of Directors appointed Bengt Sjöholm as new Chairman. Bengt Sjöholm has a vast experience from the medtech industry and has served as Board Director since 2019.お知らせ • May 03Integrum AB (Publ) Appoints Karin Ganlöv as Chief Medical OfficerIntegrum (publ) announced that the company has appointed Karin Ganlöv as chief medical officer (CMO). Karin Ganlöv joined the company in April and will be part of the management team. Karin Ganlöv is a board-certified specialist physician in cardiothoracic surgery with almost a decade of clinical experience. She has 20 years of experience in the life science industry and joins most recently from a position as VP Global Medical Affairs at Cochlear.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director Patric Lindgren was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 20% share price gain to €4.75, the stock trades at a trailing P/E ratio of 58.3x. Average forward P/E is 32x in the Medical Equipment industry in Germany. Total loss to shareholders of 21% over the past year.Reported Earnings • Mar 05Third quarter 2022 earnings: Revenues exceed analyst expectationsThird quarter 2022 results: Revenue: kr20.5m (up 88% from 3Q 2021). Net income: kr532.0k (up 61% from 3Q 2021). Profit margin: 2.6% (down from 3.0% in 3Q 2021). Revenue exceeded analyst estimates by 17%. Over the next year, revenue is forecast to grow 55%, compared to a 11% growth forecast for the industry in Germany.お知らせ • Mar 04Integrum AB (publ) to Report Fiscal Year 2022 Results on Jun 10, 2022Integrum AB (publ) announced that they will report fiscal year 2022 results on Jun 10, 2022Valuation Update With 7 Day Price Move • Feb 18Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €5.43, the stock trades at a forward P/E ratio of 600x. Average forward P/E is 32x in the Medical Equipment industry in Germany. Total returns to shareholders of 1.3% over the past year.Valuation Update With 7 Day Price Move • Jan 10Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to €5.91, the stock trades at a forward P/E ratio of 618x. Average forward P/E is 36x in the Medical Equipment industry in Germany. Total returns to shareholders of 21% over the past year.Reported Earnings • Dec 08Second quarter 2022 earnings: EPS in line with expectations, revenues disappointSecond quarter 2022 results: EPS: kr0.90 (up from kr0.19 in 2Q 2021). Revenue: kr11.9m (down 5.5% from 2Q 2021). Net income: kr16.2m (up 428% from 2Q 2021). Revenue missed analyst estimates by 4.9%. Over the next year, revenue is forecast to grow 92%, compared to a 13% growth forecast for the industry in Germany.Breakeven Date Change • Sep 08Forecast to breakeven in 2023The analyst covering Integrum expects the company to break even for the first time. New forecast suggests the company will make a profit of kr12.0m in 2023. Average annual earnings growth of 101% is required to achieve expected profit on schedule.Reported Earnings • Sep 04First quarter 2022 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: kr15.9m (up 121% from 1Q 2021). Net income: kr1.23m (up kr4.56m from 1Q 2021). Profit margin: 7.7% (up from net loss in 1Q 2021). The move to profitability was driven by higher revenue.Reported Earnings • Jun 05Full year 2021 earnings released: kr0.038 loss per share (vs kr1.04 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: kr43.1m (up 56% from FY 2020). Net loss: kr601.7k (loss narrowed 96% from FY 2020).お知らせ • Mar 05Art Clinic, Center of Excellence in the Nordic countries, has treated its first patient with Integrum's OPRA™ Implant SystemOn March 4th, teams from Integrum and Art Clinic conducted the first operation with the OPRA™ Implant System at Art Clinic's medical facility in Jönköping. The operation, which was a first stage surgery, went very smoothly. As previously described, the full treatment consists of two surgical procedures, with a healing period of between 3 to 6 months in between; and shortly thereafter, the prosthesis is then connected to the integrated implant.Reported Earnings • Mar 05Third quarter 2021 earnings releasedThe company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr14.6m (up 74% from 3Q 2020). Net income: kr329.6k (up kr4.25m from 3Q 2020). Profit margin: 2.3% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue.お知らせ • Feb 24BG Klinik Tübingen to Treat Thumb Amputees with Integrum's OPRA Implant SystemOn January 27th, the Department of Hand, Plastic, Reconstructive and Burn Surgery of the BG Trauma Center in Tübingen treated its first patients with the OPRA Implant System, and became one of the first hospitals in Germany to utilize the technology in the treatment of thumb amputees. The department is an integral part of the BG Trauma Center and the Eberhard Karls University Tübingen. One of its main foci of treatment is the functional reconstruction of extremities. In the clinic, the specialists develop an individual treatment concept for each patient, and accompany them through the full rehabilitation process; from the accident itself, to the patient's return to a normal, active, everyday life. While BG hospitals are medical facilities of the statutory accident insurance (Berufsgenossenschaft), they are open to all patients, regardless of their health insurance scheme.お知らせ • Feb 18Integrum AB Collaboration with Onkos Pave the Way for Further Growth in the USIntegrum AB (publ) announced that the collaboration with Onkos is truly starting to pay off. Not only has Onkos recruited a number of well reputed hospitals (among which Emory Healthcare, USC Keck Medical Center, and Duke Health) to the OPRA network, these hospitals are now performing their first surgeries with the OPRA Implant System and their respective patient treatment plans, and have new patients in the pipeline. Despite the ongoing pandemic, and the subsequent current restrictions placed on elective surgery, these first surgeries have been successfully performed, and further treatments scheduled. Integrum is very pleased with the recent progress made by Onkos, and the company very much looking forward to a continued expansion of collaboration. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Integrum は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:6Y1 - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数4/30/202696-46-58-41N/A1/31/202698-38-50-39N/A10/31/2025103-30-53-41N/A7/31/2025103-31-46-34N/A4/30/202598-31-50-38N/A1/31/202597-20-59-45N/A10/31/2024105-15-45-31N/A7/31/2024115-2-29-17N/A4/30/20241104-24-13N/A1/31/2024100-4-20-9N/A10/31/202387-19-22-14N/A7/31/202374-18-30-22N/A4/30/202378-16-36-25N/A1/31/202381-7-48-27N/A10/31/2022767-60-31N/A7/31/20226619-59-25N/A4/30/20226121-50-20N/A1/31/20225216-33-16N/A10/31/20214916-13-5N/A7/31/2021492-15-14N/A4/30/202144-2-7-5N/A1/31/202139-4-4-2N/A10/31/202035-9-12-12N/A7/31/202031-14-12-12N/A4/30/202028-16-19-19N/A1/31/202023-20N/A-28N/A10/31/201921-24N/A-29N/A7/31/201925-24N/A-26N/A4/30/201926-25N/A-25N/A1/31/201926-23N/A-24N/A10/31/201822-23N/A-20N/A7/31/201817-23N/A-18N/A4/30/201819-18N/A-17N/A1/31/201820-17N/A-25N/A10/31/201724-10N/A-16N/A7/31/201722-9N/A-17N/A4/30/201723-6N/A-7N/A1/31/2017240N/A4N/A4/30/2016180N/A-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 6Y1の予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 6Y1の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 6Y1の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 6Y1の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 6Y1の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 6Y1の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/31 13:27終値2026/07/31 00:00収益2026/04/30年間収益2026/04/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Integrum AB (publ) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Ulrik TrattnerDNB Carnegie Commissioned Research
お知らせ • Nov 13Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023Integrum AB (publ) provided earnings guidance for the second quarter of 2023. The revenue for second quarter is expected to be at SEK 27.5 million (SEK 20.2 million), which corresponds to an increase of 36.2% in comparison to last year. The operating profit for second quarter is expected to be at SEK 6.4 million (SEK 0.9 million). Excluding direct currency effects, the operating profit is expected to be at SEK 4.1 million (loss of SEK 5.2 million). The increase in operating profit can be attributed to both the increase in activity but also an improved cost structure for operating costs.
Breakeven Date Change • Sep 08Forecast to breakeven in 2023The analyst covering Integrum expects the company to break even for the first time. New forecast suggests the company will make a profit of kr12.0m in 2023. Average annual earnings growth of 101% is required to achieve expected profit on schedule.
Reported Earnings • Jun 04Full year 2026 earnings released: kr1.98 loss per share (vs kr1.52 loss in FY 2025)Full year 2026 results: kr1.98 loss per share (further deteriorated from kr1.52 loss in FY 2025). Revenue: kr96.1m (down 1.4% from FY 2025). Net loss: kr46.3m (loss widened 50% from FY 2025). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings.
お知らせ • Jun 04+ 3 more updatesIntegrum AB (publ) to Report Second Half, 2027 Results on Jun 10, 2027Integrum AB (publ) announced that they will report second half, 2027 results on Jun 10, 2027
Board Change • May 20High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. Founder, Owner, Chief Medical & Scientific Officer and Chairman of the Board Rickard Branemark is the most experienced director on the board, commencing their role in 2009. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Feb 12Integrum AB (publ) Announces Executive ChangesIntegrum AB (publ) announced that Jeff Zanni, President US, is leaving the company. Dr. Rickard Brånemark takes on the role as Chief Medical and Scientific Officer on a consulting basis, with responsibility for leading the training of surgeons in the use of the company's implant system both in the US and other parts of the world. On March 16, Per Nilsson, with extensive experience in production and supply chain management within the MedTech sector, will join as Chief Supply Chain Officer. Following the organizational changes, Integrum's management team consists of Martin Hillsten, Chief Executive Officer, Louise Wåhlin, Chief Financial Officer, Dr. Annika Fahlén, Director of Quality Assurance and Regulatory affairs, Dr. Rickard Brånemark, Chief Medical and Scientific Officer, and Per Nilsson, Chief Supply Chain Officer (assuming the role on March 16).
お知らせ • Oct 31Integrum AB (publ), Annual General Meeting, Oct 29, 2025Integrum AB (publ), Annual General Meeting, Oct 29, 2025.
お知らせ • Oct 16Integrum AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 42.668656 million.Integrum AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 42.668656 million. Security Name: Class B Shares Security Type: Common Stock Securities Offered: 5,333,582 Price\Range: SEK 8 Transaction Features: Rights Offering
お知らせ • Sep 01Integrum AB (publ) to Report Q4, 2026 Results on Jun 04, 2026Integrum AB (publ) announced that they will report Q4, 2026 results on Jun 04, 2026
お知らせ • Jun 03+ 1 more updateIntegrum AB (publ) to Report Q3, 2026 Results on Mar 02, 2026Integrum AB (publ) announced that they will report Q3, 2026 results on Mar 02, 2026
お知らせ • May 06Integrum AB (Publ) Announces CEO ChangesIntegrum AB (publ) announced the appointment of Martin Hillsten as the new CEO, effective immediately. He succeeds acting CEO Scott Flora, who will continue to support US marketing activities in an advisory capacity and remain on the company's Board of Directors. Martin Hillsten most recently served as CEO of Integration Diagnostics and has extensive experience in the sales and marketing of advanced medical devices in the US and other parts of the world. Integrum is implementing a strategic shift to accelerate market penetration of the OPRA® Implant System, concentrating on the US and prioritized European countries. The strategy includes a focus on selected Centers of Excellence, a strengthened aftermarket approach, and an optimization of operations that is expected to generate cost savings of up to SEK 20 million annually when fully implemented in early 2026. Martin Hillsten, born in 1978, holds a Bachelor of Business Administration from the University of Lincoln, UK, and has 20 years of experience in the life sciences industry with an emphasis on implant products and diagnostic imaging. He most recently served as CEO of Integration Diagnostics, a company that develops, manufactures and markets products to measure the stability of an implant and its ability to integrate with bone tissue (osseointegration). In addition, Martin Hillsten has held senior sales and marketing positions at Bracco Diagnostics. He currently owns 42,000 shares in Integrum. Scott Flora will continue to support the implementation of Integrum's marketing strategy in the US in an advisory role and will remain on the company's Board of Directors.
お知らせ • Mar 18Integrum AB (publ) Announces Newly Published Independent Study from the Walter Reed National Military Medical Center in Bethesda, Maryland, U.SIntegrum AB (publ) announced that a newly published independent study from the Walter Reed National Military Medical Center in Bethesda, Maryland, U.S., provides compelling evidence of OPRATM Implant System's treatment effectiveness in transfemoral amputees. The study demonstrates significant functional improvements over traditional socket prostheses, an important validation of Integrum's innovative technology and its clinical benefit in patients who have undergone amputation. The two-year follow-up study (Level II Evidence) includes the latest and most advanced version of the OPRATM Implant system, which was introduced in 2017. The study results highlight several key benefits for patients using the implant system, including increased prosthetic use, improved mobility, and enhanced quality of life. Importantly, the study reveals improved outcomes compared to previously published data, including fewer infections and complications, and a 100% implant survival rate. Collectively, the insights gathered from this study will be useful in driving further adoption of the technology by US health providers, as well as to increase the awareness of the OPRATMImplant System among health professionals and potential patients. The study was authored by Benjamin K. Potter, MD, Jonathan A. Forsberg, MD, PhD, LCDR Ashley B. Anderson, MD, MD, MD, MD., Jason M. Souza, MD, and Julio Rivera, PhD, and recently published in Clinical Orthopaedics and Related Research (CORR).
お知らせ • Mar 03Integrum AB (publ) to Report Q1, 2026 Results on Sep 01, 2025Integrum AB (publ) announced that they will report Q1, 2026 results on Sep 01, 2025
お知らせ • Feb 19Integrum AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 31 million.Integrum AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 31 million. Security Name: Class B Shares Security Type: Common Stock Securities Offered: 1,937,500 Price\Range: SEK 16 Transaction Features: Subsequent Direct Listing
お知らせ • Jan 22Integrum AB (Publ) Announces Board AppointmentsIntegrum AB (publ) announced the new board members Kristofer Westergren and Anette Lindqvist elected on the Extra General Meeting. Kristofer Westergren represents a group of major private shareholders in Integrum AB. He has followed the company closely for several years and thus has extensive knowledge of the business. Kristofer Westergren has extensive experience from the stock market as an investor and financial advisor to company managements in listed companies. He has founded and invested in several growth companies, and he has worked on the board of directors with operational improvements, value-creating acquisitions and company sales such as Sharkmob AB, KitchenTime Group AB and Corpura Fondkommission AB. Anette Lindqvist holds a degree in Business Administration from the Gothenburg School of Economics and Executive Independent Courses from Harvard Business School in Boston and the Indian Institute of Management in Bangalore. With over 30 years of experience in the life science sector, she has held several senior positions in business development and senior positions in finance at companies such as AstraZeneca Plc., SOBI, Getinge and Mölnlycke Healthcare. She has also been active in GU Ventures and Chalmers. Anette is the founder of Lynton Management AB. Currently, she is the Deputy CEO and Chairman of the Board of both Lynton Management AB and Bueneman Medic AB. She is also the CFO at Xbrane Biopharma.After the Extra General Meeting the Board of Directors in Integrum consists of the Chairman of the Board Bengt Sjöholm and the board members Rickard Brånemark, Karin Wingstrand, Cecilia Wikström, Andrew Christensen, Scott Flora, Anette Lindqvist and Kristofer Westergren.
お知らせ • Dec 20Integrum AB (Publ) Announces Board ChangesIntegrum AB (publ) announced that the election committee of Integrum plans to propose the election of Anette Lindqvist as board member at an extra general meeting. Board member Patric Lindgren has informed the election committee that he has resigned from the board on December 18. Notice of the extraordinary general meeting will be issued shortly. Anette Lindqvist has a degree in business administration from Gothenburg School of Economics and executive independent courses from Harvard Business School in Boston and the Indian Institute of Management in Bangalore. With over 30 years of experience in the Life Science sector, she has held several leading positions in business development and senior positions in finance at companies such as AstraZeneca Plc., SOBI, Getinge and Mölnlycke Healthcare. She has also worked within GU Ventures and Chalmers. Anette is the founder and chairman of the board of Lynton Management AB. Currently, she is deputy managing director and chairman of the board for both Lynton Management AB and Bueneman Medic AB.
お知らせ • Sep 18Inger Rydin Announces Executive ChangesIntegrum AB (publ) announces that Inger Rydin has been appointed interim COO and will be responsible for operations at the office in Mölndal, Sweden. Inger, who served as interim COO at Integrum from 2021 to 2023, will be part of the management team. She takes office immediately. Inger Rydin served as acting COO at Integrum from 2021 to 2023. She built a career in various leading strategic and operational positions at Essity, Mölnlycke Healthcare and Coloplast. Inger has also been CEO of fast-growing owner-managed companies and has served on the boards of companies listed in Oslo and Stockholm.
お知らせ • Sep 16+ 1 more updateIntegrum Announces Change in Chief Executive OfficerIntegrums CEO Rickard Brånemark has on September 15, 2024 agreed together with the board that he will leave the CEO role. The board announces that Scott Flora, board member since 2023, has been appointed acting CEO of Integrum AB. He takes office with immediate effect. The board will immediately start the recruiting process of a new CEO. Scott Flora was born in 1955 and is an American citizen and has a bachelor's degree in marketing from Millikin University in the United States and has attended INSEADs global programs in France. Scott is a MedTech veteran who has held leadership positions at Smith & Nephew Ioptex (Ophthalmology), and Covidien Surgical Device, Medtronic. Scott has previously, among other things, been CEO of Invuity now part of Stryker, OmniGuide, and Conventus Orthopaedics. He is now in addition to acting CEO and board member of Integrum, chairman of the board of Palliare Ltd, board member of MAKO Surgical, now part of Stryker, board member of TubeWriter and Origami Surgical. Scott has previously advised Metalmark Capital and CVC Capital. Scott owns no shares in the company.
Reported Earnings • Sep 03First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: kr19.8m (down 4.6% from 1Q 2024). Net loss: kr9.41m (loss widened 229% from 1Q 2024). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.
お知らせ • Aug 29Integrum AB (publ), Annual General Meeting, Sep 25, 2024Integrum AB (publ), Annual General Meeting, Sep 25, 2024, at 16:00 W. Europe Standard Time. Location: goco health innovation city, gemenskapens g 9, 431 53, molndal Sweden
Board Change • Jun 19Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director Patric Lindgren was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
New Risk • Jun 15New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (25% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (6.5% increase in shares outstanding). Market cap is less than US$100m (€90.0m market cap, or US$96.3m).
Reported Earnings • Jun 05Full year 2024 earnings released: EPS: kr0.23 (vs kr0.88 loss in FY 2023)Full year 2024 results: EPS: kr0.23 (up from kr0.88 loss in FY 2023). Revenue: kr116.3m (up 50% from FY 2023). Net income: kr4.17m (up kr20.4m from FY 2023). Profit margin: 3.6% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
お知らせ • May 31+ 3 more updatesIntegrum AB (publ) to Report Q3, 2025 Results on Mar 03, 2025Integrum AB (publ) announced that they will report Q3, 2025 results on Mar 03, 2025
お知らせ • May 16Integrum Announces It Has Been Granted A Registered Trademark for OPRA® Implant System in the EuIntegrum (publ) announced that the European Union Intellectual Property Office, EUIPO, has approved Integrum's product registration application for the OPRA® Implant System. Until now, the OPRA® Implant system has been an unregistered mark without legal protection. As it is granted a registered trademark, Integrum now obtains unitary immaterial protection for the product in the entire territory of the EU.
Reported Earnings • Mar 05Third quarter 2024 earnings released: EPS: kr0.05 (vs kr0.74 loss in 3Q 2023)Third quarter 2024 results: EPS: kr0.05 (up from kr0.74 loss in 3Q 2023). Revenue: kr32.9m (up 68% from 3Q 2023). Net income: kr846.0k (up kr14.4m from 3Q 2023). Profit margin: 2.6% (up from net loss in 3Q 2023). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
お知らせ • Feb 24Integrum AB (publ) to Report Q3, 2024 Results on Feb 29, 2024Integrum AB (publ) announced that they will report Q3, 2024 results on Feb 29, 2024
Reported Earnings • Dec 07Second quarter 2024 earnings released: EPS: kr0.21 (vs kr0.21 in 2Q 2023)Second quarter 2024 results: EPS: kr0.21 (down from kr0.21 in 2Q 2023). Revenue: kr36.3m (up 69% from 2Q 2023). Net income: kr3.88m (down 3.8% from 2Q 2023). Profit margin: 11% (down from 19% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.
New Risk • Dec 06New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 8.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings are forecast to decline by an average of 8.7% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable next year (kr17m net loss next year). Market cap is less than US$100m (€64.2m market cap, or US$69.3m).
お知らせ • Nov 15Integrum AB (publ) Plans to Submit a PMA Application to the FDA for the Use of OPRA in Transhumeral Implantations Based on Existing Clinical DataIntegrum (publ) announced that the company has held a pre-submission meeting with the US Food and Drug Administration (FDA) to discuss the regulatory pathway for the use of Integrum's OPRA Implant System in transhumeral amputations. Based on the conclusions from the meeting, Integrum plans to submit a Pre-Market Approval (PMA) application based on existing clinical data. Since December 2020, the OPRATM Implant System holds a PMA for the treatment of transfemoral (above-knee) amputations. As the OPRATM Implant System is equally functional in transhumeral (above-elbow) amputations, Integrum aims to broaden the regulatory approval in the US. After a recent pre-submission meeting held with the FDA and additional internal analysis and dialogue with the FDA, Integrum has reason to believe that existing clinical data on the transhumeral (above elbow) amputation level may be sufficient to qualify for a PMA. Integrum will therefore intensify the work to compile and submit a PMA application within the first half of 2024.
お知らせ • Nov 13Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023Integrum AB (publ) provided earnings guidance for the second quarter of 2023. The revenue for second quarter is expected to be at SEK 27.5 million (SEK 20.2 million), which corresponds to an increase of 36.2% in comparison to last year. The operating profit for second quarter is expected to be at SEK 6.4 million (SEK 0.9 million). Excluding direct currency effects, the operating profit is expected to be at SEK 4.1 million (loss of SEK 5.2 million). The increase in operating profit can be attributed to both the increase in activity but also an improved cost structure for operating costs.
お知らせ • Nov 11Integrum AB (publ) to Report Q2, 2024 Results on Dec 04, 2023Integrum AB (publ) announced that they will report Q2, 2024 results on Dec 04, 2023
お知らせ • Nov 10Integrum (Publ) Announces US Department of Defense Decided to Fully Fund a Clinical Study of OPRA(TM) Implant System on Up to 30 Patients with Transtibial (Below-Knee) AmputationsIntegrum (publ) announced that the US Department of Defense has decided to fully fund a clinical study of OPRA(TM) Implant System on up to 30 patients with transtibial (below-knee) amputations. As previously announced, the study will be performed by the Walter Reed National Military Medical Center in Bethesda, Maryland. Integrum will supply OPRA(TM) Implant Systems to Walter Reed on commercial terms. The OPRA(TM) Implant System clinical study on the below-knee amputation level recently received FDA approval, and recruitment to the study will start as soon as the protocol is approved by the Investigational Research Board (IRB). Once the study is finalized, Integrum will be able to use the data in any future regulatory process.
お知らせ • Oct 31Integrum's Opra™? Implant System Gets Fda Approval for Clinical Study on Below-Knee AmutationationsIntegrum (publ) announced that the company's OPRA Implant system is approved by FDA to be used in a clinical study on below-knee amputations in the US. The clinical study will be important for the future approval of the OPRA™? Implant System on the below-knee amputations level, which is the most frequent amputation level. The study will be performed by the Walter Reed National Military Medical Center.
New Risk • Oct 18New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: kr6.0m Forecast net loss in 1 year: kr7.2m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (kr7.2m net loss next year). Market cap is less than US$100m (€51.6m market cap, or US$54.3m).
お知らせ • Oct 13Integrum (Publ) Announces Long-Term Follow-Up Patient Who Received A Human-Machine Bionic Hand Prosthesis, UtilizingIntegrum (publ) announced that the long-term follow-up of a patient who received a human-machine bionic hand prosthesis, utilizing the company's innovative implantable solution, has shown successful results. The groundbreaking system represents a future standard of advanced prosthetic solutions. The patient case involves a Swedish woman who lost her right hand in a tragic accident over 20 years ago. Following reconstructive surgery, the woman received a below-elbow prosthesis based on Integrum's OPRATM Implant System solution. The system was further refined advanced e-OPRATM system with implanted electrodes, connected to a sophisticated AI system with the capability of relaying impulses, both to and from, a bionic hand equipped with heat and touch sensors.
お知らせ • Oct 12Integrum Announces Long-Term Integrated Bionic Hand Enriched with Motor and Sensory AIIntegrum (publ) announced that the long-term follow-up of a patient who received a human-machine bionic hand prosthesis, utilizing the company's innovative implantable solution, has shown successful results. The system represents a future standard of advanced prosthetic solutions. The patient case involves a Swedish woman who lost her right hand in a tragic accident over 20 years ago. Following reconstructive surgery, the woman received a below-elbow prosthesis based on Integrum's OPRATM Implant System solution. The system was further refined advanced e-OPRATM system with implanted electrodes, connected to a sophisticated AI system with the capability of relaying impulses, both to and from, a bionic hand equipped with heat and touch sensors. The complete system has been used at home, allowing the carrier to perform simple and motorically complex everyday tasks. This is the first time clinicians and researchers have been able to achieve a long-term human-machine interface, connecting residual bones, nerves, and muscles into an electronic system to regain mobility.
お知らせ • Oct 11Integrum Receives Unitary Patent for Neuromotus in the EUIntegrum (publ) announced that the company has received a Unitary Patent approval pertaining to NeuromotusTM - a clinical innovation aimed at treating patients suffering from Phantom Limb Pain. The new patent process, which was installed by the EU in June 2023, grants immediate proprietary rights to Integrum in 17 separate European countries. Integrum develops NeuromotusTM, an innovative therapy designed to treat patients suffering from phantom pain. The therapy is based on a non-invasive technology utilizing smart devices to process and decode electrical muscle signals. These are connected to virtual and augmented reality (AR-VR) systems, allowing the patient to control the missing limb in a virtual environment. This form of treatment has been proven effective to combat chronic pain. The current patent will be taken to effect on 23rd of August, 2023, and thus grants Integrum exclusive commercial rights for NeuromotusTM on several European key markets, including Germany, Benelux, France, Italy, and Sweden. The patent will be valid until 19th of December, 2034.
お知らせ • Oct 10Integrum AB (Publ) Appoints Scott Flora as Full Board MemberIntegrum AB (publ) announced that Scott Flora was recently elected as full member of the company's board at the annual general meeting. Mr. Flora was appointed as Adjunct Board Member in May 2023. At the annual general meeting on September 27, he was elected full member of the board together with Rickard Brånemark, Andrew Christensen, Bengt Sjöholm, Karin Wingstrand, Patric Lindgren, and Cecilia Wikström, who were all re-elected. Scott Flora serves concurrently as chairman of the Board at Palliare Ltd. and New View Surgical, and as board member at CytoVeris and Origami Surgical. He has previous experience as board member from Invuity (acquired by Stryker), MAKO Surgical, and Tengion. Mr. Flora is active as Strategic Advisor to CareSyntax, MiCarePath, and Integrum. Furthermore, he has over 40 years of experience from C-suite leadership positions in global companies, including Invuity, Conventus Orthopaedics, OmniGuide Surgical, and Smith & Nephew Orthopedics.
お知らせ • Sep 14Integrum Initiates A Strategic Review Process to Accelerate GrowthIntegrum AB (publ) announces that its Board of Directors has initiated a review and evaluation of strategic alternatives to further accelerate the global roll-out of its unique OPRA™Implant System. Integrum has developed and markets the OPRA™ Implant System, an advanced prosthesis fixation system for individuals with mobility challenges due to limb amputation. Integrum's implant solution is surgically inserted into the patient's skeleton - providing greatly increased functionality and significantly fewer complications than conventional socket prostheses. As a next step in revolutionizing the prosthesis market, Integrum is developing the e-OPRATM Implant System - the world's first mind-controlled robot prosthesis capable of transmitting sensory feedback. Integrum is experiencing rapid growth of its business and recently reported its highest quarterly sales revenue ever. The long-term goal is to establish OPRATM Implant Systems as the worldwide standard of care for individuals with mobility challenges. The strategic review aims to ensure that the global roll-out of Integrum's implant systems is conducted most efficiently, in the interest of both patients and shareholders. As part of the process, the Board will consider a full range of strategic alternatives, including mergers or other business combinations, strategic investments, sale of all or a portion of the company's assets, corporate sale, or other significant transactions. As part of the strategic review process, Integrum has engaged Incentrum - a global merchant bank based in New York City - as its financial advisor to advise the company regarding this broad and comprehensive review and analysis of strategic alternatives. Integrum has not set a timetable for completion of the process and does not plan to provide any updates on developments unless and until the company executes a definitive agreement with respect thereto or the Board determines to conclude the strategic review. While the company intends to evaluate all options fairly to maximize shareholder value, there can be no assurance that the strategic review process will result in any transaction, or if a transaction is undertaken, as to its terms or timing.
お知らせ • Sep 09Integrum AB Receives Reimbursement Code for Axor IIIntegrum (publ) announced that The Centers for Medicare and Medicaid Services (CMS) have granted theosseointegrated external prosthetic connection device Axor II a new reimbursement code. The new code, which is expected to take effect in October, is connected to a set reimbursement that will help to drive growth in the US. The new CMS-specific code is granted based on a preliminary benefit category determination that the Axor(TM) II Ossteointegrated External Prosthetic Connection Device is used in addition to a lower extremity prosthesis and, therefore, falls under the Medicare benefit for artificial legs (prosthetics). Since the Axor(TM)II utilizes a standard 4-hole male/female mounting system, the OPRA(TM) Implant System can be connected to commercially available prosthetic systems that utilize this standardized connection method. The Axor(TM) II acts like aski-binding and releases the prosthesis if overload occurs, reducing the risk of damage to the implant and the skeleton. Axor(TM) II was first approved under a Premarket Approval (PMA) application by the Food and Drug Administration (FDA) on December 18, 2020.
お知らせ • Jul 14Integrum (Publ) Announces First Case Study of A Person with Above-Elbow Implantation Obtains Unprecedented Control of Every Finger in A Bionic HandIntegrum (publ) announced that the first case study of a person with above-elbow amputation obtaining unprecedented control of every finger in a bionic hand has been published in Science Translational Medicine. By combining Integrum's OPRA™? Implant System and e-OPRA™? Implant System with revolutionary surgical and engineering advancements and AI algorithms, the user's intentions were translated into the movement of the bionic fingers. The scientific paper illustrates how Integrum's technology combined with advanced reconstructive surgery and AI for the first time, made it possible for an above-elbow amputee patient to control every finger of a prosthetic hand as if it were his own. The surgery took place at the Sahlgrenska University Hospital and combined new microsurgical techniques with sophisticated implanted electrodes that provide single-finger control of a prosthetic arm as well as sensory feedback. The embedded neuromuscular sensors were connected to an electronic system via Integrum's bone-anchored interface (OPRA(TM) Im plant System and e-OPRA(TM) Implant System), and AI algorithms in the electronic system translated the user's intentions into prosthetic finger movements.
お知らせ • Jun 17Integrum AB (Publ) Announces Management ChangesIntegrum (publ) announced that the company has appointed Jeffrey Zanni as President, U.S., succeeding Thomas Dugan, who has decided to resign from his position. Jeffrey Zanni joins Integrum from Conventus Flower Orthopedics, where he has been Chief Commercial Officer. He has more than 20 years of success in the surgical and medical device industry and has a proven track record of successfully developing and leading highly effective sales teams. Jeffrey Zanni has previously held several executive positions at companies like Vyaire Medical, Tornier Orthopedics Stryker Orthopedics, and Pfizer. Jeffrey Zanni has experience launching new products and developing effective clinician and patient support programs from his previous positions. He has a deep understanding of how to partner with key stakeholders within the U.S. Jeffrey Zanni will join Integrum on 2023-07-03.
New Risk • Jun 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (€27.0m market cap, or US$29.0m).
Reported Earnings • Jun 09Full year 2023 earnings releasedFull year 2023 results: Revenue: kr98.5m (up 62% from FY 2022). Net loss: kr3.72m (down 118% from profit in FY 2022). Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany.
お知らせ • May 12Integrum Announces the Appointment of Scott Flora as Adjunct Board MemberIntegrum (publ) announced that Scott Flora has been appointed as an adjunct board member effective immediately. Scott Flora brings vast and extensive competence to the company as Integrum is reinforcing the company's position as a leader of osseointegrated implant systems. Scott Flora has over 40 years of experience in strategic and leadership roles in the healthcare sector, particularly in surgical devices, and has held prominent leadership positions at companies including Covidien and Smith & Nephew. He is currently Chairman of the Board at Palliare Ltd. and a board member at CytoVeris and New View Surgical. Scott Flora also serves as Strategic Advisor to CareSyntax, MiCarePath, and Integrum. He has previously held several leading positions roles as President and CEO of Invuity (acquired by Stryker), Executive Director of Conventus Orthopaedics, President and CEO of OmniGuide Surgical, President of Covidien's Surgical Device Group, President of Smith& Nephew Orthopedic Reconstruction and General Manager at Smith&Nephew Trauma. Scott Flora has also served on the company boards of Invuity (acquired by Stryker), MAKO Surgical, and Tengion.
Reported Earnings • Mar 04Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr22.1m (up 58% from 3Q 2022). Net loss: kr13.6m (down kr14.1m from profit in 3Q 2022). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.
お知らせ • Jan 21Integrum (publ) Appoints Annika Fahlén as Director of Quality Assurance and Regulatory Affairs, Effective 1 April 2023Integrum (publ) announced that the company has appointed Annika Fahlén as Director of Quality Assurance and Regulatory Affairs, QARA. Annika Fahlén will join the company on 1 April 2023 and will be part of the management team. Annika Fahlén has vast experience in the field of Quality Assurance and Regulatory Affairs working at Mölnlycke, Getinge, Qing and Abigo. She will join Integrum from a position as Regulatory Affairs Quality Assurance Director at Essity.
お知らせ • Jan 20Integrum AB (Publ) Announces Dennis Baecklund to Leave the Company as CFOIntegrum AB (publ) announces that the company's CFO Dennis Baecklund has decided to leave the company. He will remain in his position until the end of March 2023 and the recruitment of a successor will begin immediately. Dennis Baecklund joined Integrum as Chief Financial Officer in October 2019.
Reported Earnings • Dec 02Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr32.4m (up 173% from 2Q 2022). Net income: kr2.32m (down 86% from 2Q 2022). Profit margin: 7.2% (down from 136% in 2Q 2022). Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany.
お知らせ • Dec 01Integrum Provides an Update on the Clinical Development Programs of e-OPRATM Implant System and NeuromotusIntegrum (publ) provides an update on the clinical development of its mobility-transforming implant solution e-OPRATM Implant System, and NeuromotusTM - a cutting-edge technology developed to prevent severe pain in limb loss patients. e-OPRATM Implant System: The clinical development of e-OPRA™ Implant System focuses not only on providing prosthesis users with the benefits of a bone-anchored implant solution but also on the possibilities of mind-controlled artificial limb movement, as well as re-established sensory feedback to the central nervous system. e-OPRATM is currently being evaluated in three clinical trials. Two clinical trials are being conducted in the US, at the Brigham and Women's Hospital in collaboration with Massachusetts Institute of Technology in Boston, and University of California in San Francisco,. The trials aim to evaluate the extent by which a person who has received the e-OPRA™ Implant System can exhibit full neural control over a neuro-mechanical prosthetic system, as well as the normalization in walking metrics. The functionality of the e-OPRATM Implant System is being evaluated at two levels: in patients who have undergone amputation above the knee, and in patients with below knee amputations. The third trial is conducted at the Sahlgrenska University Hospital, in Sweden. This trial aims to evaluate potential improvements in prosthetic control in patients who have received e-OPRATM Implant System following upper limb amputation. To assess prosthetic control performance, the trial will measure long-term myoelectric signal stability and sensory perception over twelve months.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director Patric Lindgren was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Nov 02Investor sentiment improved over the past weekAfter last week's 25% share price gain to €2.63, the stock trades at a trailing P/E ratio of 27.5x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total loss to shareholders of 71% over the past year.
お知らせ • Oct 12Integrum AB (publ) Is Granted Patent Approval for Its OPRA Implant System from the Us Patent and Trade OrganizationIntegrum (publ) announced that the company has received a patent approval in the US describing components and design features of the OPRATM Implant System, including elements that were implemented in 2017 and later were granted a PMA approval in late 2020. The patent period extends until 2044. Integrum develops the OPRATM Implant System, a revolutionary implant technology based on the company's deep expertise and innovations in osseointegration, that help amputees regain normal mobility and quality of life. The current patent includes claims covering the system as a whole, including the anchoring solution for attaching a prosthesis into the human body as well as the abutment and the abutment screw. These claims extend beyond transfemoral applications, which currently make up the majority of treatment cases, to include treatment in other types of long bone prosthetic applications, such as the upper arm or lower leg. Further, the claims cover design features for the connection between the abutment and the fixture, allowing a pathway for communication of physical and biophysical signals between inside and outside of the human body. Such design aspects are of vital importance to, for example, the e-OPRATM Implant System - Integrum's state-of-the-art mind-controlled robotic prosthesis. The patent grants Integrum exclusivity to OPRATM Implant System ranging from October 11th,2022, until 2044 and is of vital importance to the continued commercial success on the world'slargest medical technology market.
Valuation Update With 7 Day Price Move • Sep 23Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €2.78, the stock trades at a trailing P/E ratio of 28.5x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total loss to shareholders of 68% over the past year.
Valuation Update With 7 Day Price Move • Sep 07Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to €3.40, the stock trades at a trailing P/E ratio of 34.7x. Average forward P/E is 26x in the Medical Equipment industry in Germany. Total loss to shareholders of 65% over the past year.
Reported Earnings • Sep 01First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr25.2m (up 95% from 1Q 2022). Net loss: kr550.0k (down 145% from profit in 1Q 2022). Over the next year, revenue is forecast to grow 76%, compared to a 8.0% growth forecast for the Medical Equipment industry in Germany.
Valuation Update With 7 Day Price Move • Jul 26Investor sentiment improved over the past weekAfter last week's 18% share price gain to €5.03, the stock trades at a trailing P/E ratio of 44.3x. Average forward P/E is 29x in the Medical Equipment industry in Germany. Total loss to shareholders of 37% over the past year.
Valuation Update With 7 Day Price Move • Jun 20Investor sentiment improved over the past weekAfter last week's 20% share price gain to €4.29, the stock trades at a trailing P/E ratio of 38.2x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total loss to shareholders of 42% over the past year.
Reported Earnings • Jun 11Full year 2022 earnings releasedFull year 2022 results: Revenue: kr76.7m (up 75% from FY 2021). Net income: kr21.3m (up kr23.4m from FY 2021). Profit margin: 28% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 27%, compared to a 7.1% growth forecast for the industry in Germany.
お知らせ • Jun 11+ 2 more updatesIntegrum AB (publ) to Report Q1, 2023 Results on Sep 02, 2022Integrum AB (publ) announced that they will report Q1, 2023 results on Sep 02, 2022
お知らせ • May 20+ 1 more updateIntegrum AB (publ) Announces Board ChangesIntegrum AB (publ) announced Rickard Brånemark resigned as Chairman of the Board, and the Board of Directors appointed Bengt Sjöholm as new Chairman. Bengt Sjöholm has a vast experience from the medtech industry and has served as Board Director since 2019.
お知らせ • May 03Integrum AB (Publ) Appoints Karin Ganlöv as Chief Medical OfficerIntegrum (publ) announced that the company has appointed Karin Ganlöv as chief medical officer (CMO). Karin Ganlöv joined the company in April and will be part of the management team. Karin Ganlöv is a board-certified specialist physician in cardiothoracic surgery with almost a decade of clinical experience. She has 20 years of experience in the life science industry and joins most recently from a position as VP Global Medical Affairs at Cochlear.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director Patric Lindgren was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 20% share price gain to €4.75, the stock trades at a trailing P/E ratio of 58.3x. Average forward P/E is 32x in the Medical Equipment industry in Germany. Total loss to shareholders of 21% over the past year.
Reported Earnings • Mar 05Third quarter 2022 earnings: Revenues exceed analyst expectationsThird quarter 2022 results: Revenue: kr20.5m (up 88% from 3Q 2021). Net income: kr532.0k (up 61% from 3Q 2021). Profit margin: 2.6% (down from 3.0% in 3Q 2021). Revenue exceeded analyst estimates by 17%. Over the next year, revenue is forecast to grow 55%, compared to a 11% growth forecast for the industry in Germany.
お知らせ • Mar 04Integrum AB (publ) to Report Fiscal Year 2022 Results on Jun 10, 2022Integrum AB (publ) announced that they will report fiscal year 2022 results on Jun 10, 2022
Valuation Update With 7 Day Price Move • Feb 18Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €5.43, the stock trades at a forward P/E ratio of 600x. Average forward P/E is 32x in the Medical Equipment industry in Germany. Total returns to shareholders of 1.3% over the past year.
Valuation Update With 7 Day Price Move • Jan 10Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to €5.91, the stock trades at a forward P/E ratio of 618x. Average forward P/E is 36x in the Medical Equipment industry in Germany. Total returns to shareholders of 21% over the past year.
Reported Earnings • Dec 08Second quarter 2022 earnings: EPS in line with expectations, revenues disappointSecond quarter 2022 results: EPS: kr0.90 (up from kr0.19 in 2Q 2021). Revenue: kr11.9m (down 5.5% from 2Q 2021). Net income: kr16.2m (up 428% from 2Q 2021). Revenue missed analyst estimates by 4.9%. Over the next year, revenue is forecast to grow 92%, compared to a 13% growth forecast for the industry in Germany.
Breakeven Date Change • Sep 08Forecast to breakeven in 2023The analyst covering Integrum expects the company to break even for the first time. New forecast suggests the company will make a profit of kr12.0m in 2023. Average annual earnings growth of 101% is required to achieve expected profit on schedule.
Reported Earnings • Sep 04First quarter 2022 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: kr15.9m (up 121% from 1Q 2021). Net income: kr1.23m (up kr4.56m from 1Q 2021). Profit margin: 7.7% (up from net loss in 1Q 2021). The move to profitability was driven by higher revenue.
Reported Earnings • Jun 05Full year 2021 earnings released: kr0.038 loss per share (vs kr1.04 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: kr43.1m (up 56% from FY 2020). Net loss: kr601.7k (loss narrowed 96% from FY 2020).
お知らせ • Mar 05Art Clinic, Center of Excellence in the Nordic countries, has treated its first patient with Integrum's OPRA™ Implant SystemOn March 4th, teams from Integrum and Art Clinic conducted the first operation with the OPRA™ Implant System at Art Clinic's medical facility in Jönköping. The operation, which was a first stage surgery, went very smoothly. As previously described, the full treatment consists of two surgical procedures, with a healing period of between 3 to 6 months in between; and shortly thereafter, the prosthesis is then connected to the integrated implant.
Reported Earnings • Mar 05Third quarter 2021 earnings releasedThe company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr14.6m (up 74% from 3Q 2020). Net income: kr329.6k (up kr4.25m from 3Q 2020). Profit margin: 2.3% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue.
お知らせ • Feb 24BG Klinik Tübingen to Treat Thumb Amputees with Integrum's OPRA Implant SystemOn January 27th, the Department of Hand, Plastic, Reconstructive and Burn Surgery of the BG Trauma Center in Tübingen treated its first patients with the OPRA Implant System, and became one of the first hospitals in Germany to utilize the technology in the treatment of thumb amputees. The department is an integral part of the BG Trauma Center and the Eberhard Karls University Tübingen. One of its main foci of treatment is the functional reconstruction of extremities. In the clinic, the specialists develop an individual treatment concept for each patient, and accompany them through the full rehabilitation process; from the accident itself, to the patient's return to a normal, active, everyday life. While BG hospitals are medical facilities of the statutory accident insurance (Berufsgenossenschaft), they are open to all patients, regardless of their health insurance scheme.
お知らせ • Feb 18Integrum AB Collaboration with Onkos Pave the Way for Further Growth in the USIntegrum AB (publ) announced that the collaboration with Onkos is truly starting to pay off. Not only has Onkos recruited a number of well reputed hospitals (among which Emory Healthcare, USC Keck Medical Center, and Duke Health) to the OPRA network, these hospitals are now performing their first surgeries with the OPRA Implant System and their respective patient treatment plans, and have new patients in the pipeline. Despite the ongoing pandemic, and the subsequent current restrictions placed on elective surgery, these first surgeries have been successfully performed, and further treatments scheduled. Integrum is very pleased with the recent progress made by Onkos, and the company very much looking forward to a continued expansion of collaboration.